Fiche du document
19 janvier 2022
- handle: 10670/1.613vjp
- doi: 10.3390/ijms222313079
Ce document est mis à disposition selon les termes de la Licence Creative Commons Attribution - Pas d’utilisation commerciale 4.0 International. / This work is licensed under a Creative Commons Attribution - NonCommercial 4.0 International License. , https://creativecommons.org/licenses/by-nc/4.0/
Mots-clés
Acute coronary syndrome Aspirin Atherothrombosis Bleeding Cardiovascular disease Dual antiplatelet therapy P2Y12 receptor antagonists PlateletsSujets proches
Hemoptysis Bleeding Haemorrhage Agency (Philosophy) Agents Person (Philosophy)Citer ce document
Georges Jourdi et al., « Current and novel antiplatelet therapies for the treatment of cardiovascular diseases », Papyrus : le dépôt institutionnel de l'Université de Montréal, ID : 10.3390/ijms222313079
Métriques
Partage / Export
Résumé
Over the last decades, antiplatelet agents, mainly aspirin and P2Y12 receptor antagonists, have significantly reduced morbidity and mortality associated with arterial thrombosis. Their pharmacological characteristics, including pharmacokinetic/pharmacodynamics profiles, have been extensively studied, and a significant number of clinical trials assessing their efficacy and safety in various clinical settings have established antithrombotic efficacy. Notwithstanding, antiplatelet agents carry an inherent risk of bleeding. Given that bleeding is associated with adverse cardiovascular outcomes and mortality, there is an unmet clinical need to develop novel antiplatelet therapies that inhibit thrombosis while maintaining hemostasis. In this review, we present the currently available antiplatelet agents, with a particular focus on their targets, pharmacological characteristics, and patterns of use. We will further discuss the novel antiplatelet therapies in the pipeline, with the goal of improved clinical outcomes among patients with atherothrombotic diseases.